Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Insulin Formulations: Types and Delivery

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Type I Diabetes I: Introduction

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...

Feedback Loops

Feedback Loops

In most cases, excessive hormone production is prevented by negative feedback—a loop that starts with a stimulus inducing the release of a particular substance, like a hormone, to maintain a certain level before triggering a signal that results in a decrease in further release of the hormone.

Type II Diabetes I: Introduction

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...

Type I Diabetes II: Pathophysiology

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Insulin Bolus Patterns in Newly Diagnosed Youth With Type 1 Diabetes Using a Hybrid Closed-Loop Insulin Delivery System.

Journal of diabetes science and technology·2026

Same author

Trends in Total Daily Dose and Variability of Insulin Requirements in Newly Diagnosed Children and Adolescents with Type 1 Diabetes over 48 Months.

Diabetes technology & therapeutics·2025

Same author

Sleep Quality and Quantity in Caregivers of Children with Type 1 Diabetes Using Closed-Loop Insulin Delivery or a Sensor-Augmented Pump.

Pediatric diabetes·2025

Same author

Impact of Ultra-Rapid Insulin on Boost and Ease-Off in the Cambridge Hybrid Closed-Loop System for Individuals With Type 1 Diabetes.

Journal of diabetes science and technology·2024

Same author

Eighteen-Month Hybrid Closed-Loop Use in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Trial.

Diabetes care·2024

Same author

Closed-Loop Therapy and Sleep in Young People Newly Diagnosed With Type 1 Diabetes and Their Parents.

Journal of diabetes science and technology·2024

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device

A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device

Published on: January 26, 2010

Simulation environment to evaluate closed-loop insulin delivery systems in type 1 diabetes.

Malgorzata E Wilinska¹, Ludovic J Chassin, Carlo L Acerini

¹Cambridge University Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK. mew37@cam.ac.uk

Journal of Diabetes Science and Technology

|February 20, 2010

Summary

This study introduces a validated in silico simulation environment for developing and testing closed-loop insulin delivery systems for type 1 diabetes mellitus (T1DM). It accelerates research by providing reliable virtual testing before human trials.

More Related Videos

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

Related Experiment Videos

Last Updated: Jun 16, 2026

A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device

A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device

Published on: January 26, 2010

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

Area of Science:

Biomedical Engineering
Computational Biology
Endocrinology

Background:

Closed-loop insulin delivery systems require extensive human trials for evaluation.
In silico testing offers a method to accelerate the development of these systems.
Type 1 diabetes mellitus (T1DM) management benefits from advanced technological solutions.

Purpose of the Study:

To present a novel simulation environment for the development and testing of closed-loop insulin delivery systems.
To support research in T1DM by providing a flexible platform for in silico experimentation.
To validate the simulation environment against existing clinical data.

Main Methods:

Development of a simulation environment with a glucose regulation model for a virtual T1DM population.
Inclusion of glucose measurement and insulin delivery models within the flexible environment.
Validation of the simulation by comparing its predictions to a clinical study on overnight closed-loop insulin delivery.

Main Results:

A detailed glucose regulation model and population values for 18 synthetic subjects were provided.
The simulation environment successfully reproduced population results from a clinical study.
The environment demonstrated its capability to model closed-loop insulin delivery in T1DM.

Conclusions:

Computer-based simulations are essential for guiding and preceding human trials of closed-loop systems.
The developed simulation environment is validated for population-based predictions.
This tool enhances efficiency and saves resources in T1DM research.